SG11201407975TA - Alternaria peptides - Google Patents
Alternaria peptidesInfo
- Publication number
- SG11201407975TA SG11201407975TA SG11201407975TA SG11201407975TA SG11201407975TA SG 11201407975T A SG11201407975T A SG 11201407975TA SG 11201407975T A SG11201407975T A SG 11201407975TA SG 11201407975T A SG11201407975T A SG 11201407975TA SG 11201407975T A SG11201407975T A SG 11201407975TA
- Authority
- SG
- Singapore
- Prior art keywords
- amino acid
- acid sequence
- polypeptide
- salt
- seq
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 12
- 241000223600 Alternaria Species 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 18
- 229920001184 polypeptide Polymers 0.000 abstract 10
- 150000003839 salts Chemical class 0.000 abstract 9
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 4
- 241001669573 Galeorhinus galeus Species 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ecology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1209868.7A GB201209868D0 (en) | 2012-06-01 | 2012-06-01 | Alternaria peptides |
| PCT/GB2013/051439 WO2013179043A1 (en) | 2012-06-01 | 2013-05-30 | Alternaria peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407975TA true SG11201407975TA (en) | 2015-01-29 |
Family
ID=46582267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407975TA SG11201407975TA (en) | 2012-06-01 | 2013-05-30 | Alternaria peptides |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20150098969A1 (enExample) |
| EP (1) | EP2855515A1 (enExample) |
| JP (1) | JP2015520771A (enExample) |
| KR (1) | KR20150028788A (enExample) |
| CN (1) | CN104507959A (enExample) |
| AU (1) | AU2013269326A1 (enExample) |
| BR (1) | BR112014029856A2 (enExample) |
| CA (1) | CA2875130A1 (enExample) |
| CL (1) | CL2014003290A1 (enExample) |
| EA (1) | EA201492268A1 (enExample) |
| GB (2) | GB201209868D0 (enExample) |
| HK (1) | HK1201752A1 (enExample) |
| IL (1) | IL235840A0 (enExample) |
| IN (1) | IN2014DN10558A (enExample) |
| MX (1) | MX2014014461A (enExample) |
| SG (1) | SG11201407975TA (enExample) |
| WO (1) | WO2013179043A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160130311A1 (en) * | 2013-06-05 | 2016-05-12 | Maria R. Diaz-Torres | T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT400723B (de) * | 1993-08-27 | 1996-03-25 | Biomay Prod & Handel | Rekombinante alternaria alternata allergene |
| JP2007176953A (ja) * | 1996-03-10 | 2007-07-12 | Meiji Milk Prod Co Ltd | アレルギー疾患に対するペプチド免疫療法剤 |
| JP2003116556A (ja) * | 2001-10-09 | 2003-04-22 | Nippon Zenyaku Kogyo Kk | アレルギー性皮膚炎治療剤 |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP2286833A3 (en) * | 2007-08-15 | 2011-09-14 | Circassia Limited | Peptides for desensibilization against allergens |
| GB0821806D0 (en) * | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| DK2619219T3 (en) * | 2010-09-24 | 2016-02-22 | Maria R Diaz-Torres | Peptides |
-
2012
- 2012-06-01 GB GBGB1209868.7A patent/GB201209868D0/en not_active Ceased
-
2013
- 2013-05-30 WO PCT/GB2013/051439 patent/WO2013179043A1/en not_active Ceased
- 2013-05-30 CN CN201380040582.XA patent/CN104507959A/zh active Pending
- 2013-05-30 AU AU2013269326A patent/AU2013269326A1/en not_active Abandoned
- 2013-05-30 KR KR20147037163A patent/KR20150028788A/ko not_active Withdrawn
- 2013-05-30 GB GB1422977.7A patent/GB2517871A/en not_active Withdrawn
- 2013-05-30 EA EA201492268A patent/EA201492268A1/ru unknown
- 2013-05-30 HK HK15102384.3A patent/HK1201752A1/xx unknown
- 2013-05-30 BR BR112014029856A patent/BR112014029856A2/pt not_active IP Right Cessation
- 2013-05-30 JP JP2015514589A patent/JP2015520771A/ja active Pending
- 2013-05-30 IN IN10558DEN2014 patent/IN2014DN10558A/en unknown
- 2013-05-30 SG SG11201407975TA patent/SG11201407975TA/en unknown
- 2013-05-30 MX MX2014014461A patent/MX2014014461A/es unknown
- 2013-05-30 EP EP13727964.2A patent/EP2855515A1/en not_active Withdrawn
- 2013-05-30 CA CA2875130A patent/CA2875130A1/en not_active Abandoned
- 2013-05-30 US US14/403,464 patent/US20150098969A1/en not_active Abandoned
-
2014
- 2014-11-23 IL IL235840A patent/IL235840A0/en unknown
- 2014-12-01 CL CL2014003290A patent/CL2014003290A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013179043A1 (en) | 2013-12-05 |
| JP2015520771A (ja) | 2015-07-23 |
| EA201492268A1 (ru) | 2015-05-29 |
| AU2013269326A1 (en) | 2014-12-18 |
| KR20150028788A (ko) | 2015-03-16 |
| GB201209868D0 (en) | 2012-07-18 |
| IL235840A0 (en) | 2015-01-29 |
| US20150098969A1 (en) | 2015-04-09 |
| MX2014014461A (es) | 2015-02-10 |
| CL2014003290A1 (es) | 2015-05-22 |
| IN2014DN10558A (enExample) | 2015-08-21 |
| CA2875130A1 (en) | 2013-12-05 |
| GB2517871A (en) | 2015-03-04 |
| BR112014029856A2 (pt) | 2017-07-25 |
| CN104507959A (zh) | 2015-04-08 |
| EP2855515A1 (en) | 2015-04-08 |
| HK1201752A1 (en) | 2015-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201407483YA (en) | Compositions and methods for modulating smn gene family expression | |
| SG11201900400QA (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201804211YA (en) | Compositions comprising bacterial strains | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201805120YA (en) | Zika virus vaccine | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201911572YA (en) | Adenoviral vectors | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof |